The longer someone took the drugs, the greater the danger.
Among the most quietly ubiquitous medications in modern life, proton pump inhibitors — taken by millions to calm the burn of acid reflux — now carry a shadow that warrants careful attention. A large longitudinal study tracking over two hundred thousand people across more than a decade has found that regular use of these drugs is associated with a meaningfully higher risk of developing type 2 diabetes, a risk that deepens the longer the medication is taken. The finding does not demand alarm, but it does invite a more deliberate conversation between patients and physicians about the true cost of long-term relief.
- A study of over 204,000 people found that regular PPI users developed type 2 diabetes at nearly double the rate of non-users — 7.44 versus 4.32 cases per 1,000 people annually.
- The risk is not static: two or more years of PPI use pushes the diabetes likelihood up by 26%, and the effect holds across genders, ages, and lifestyles, suggesting no population is insulated.
- A second class of acid-suppressing drugs, H2 blockers, also showed elevated risk at 14%, hinting that the gut itself — not just one molecule — may be the site of disruption.
- Researchers point to shifts in gut microbiota as a plausible mechanism, with altered bacterial communities potentially interfering with how the body regulates blood sugar.
- The scientific community is urging a recalibration: not abandonment of these widely prescribed drugs, but routine glucose screening for long-term users and more deliberate prescribing decisions.
A study published in the journal Gut has raised a significant question about one of the world's most commonly used drug classes: could the medications millions take daily for acid reflux be quietly increasing their risk of type 2 diabetes? The research suggests the answer may be yes.
Proton pump inhibitors — drugs like omeprazole and lansoprazole that suppress stomach acid — are prescribed globally for reflux, peptic ulcers, and indigestion. To explore their potential link to diabetes, researchers followed 204,689 participants over nine to twelve years, tracking health behaviors and outcomes from data collected since 1976. By the end of the study period, 10,105 participants had developed type 2 diabetes.
The association was consistent and dose-dependent. Regular PPI users — those taking the drugs at least twice a week — were 24% more likely to develop diabetes than non-users. That figure climbed to 26% for those who used PPIs for more than two years, while risk fell the longer someone had been off the medication. Crucially, the elevated risk appeared regardless of age, sex, diet, exercise habits, or family history, lending the finding unusual robustness.
The researchers also examined H2 blockers, a related category of acid-suppressing drugs, and found a 14% increased risk with prolonged use. Both findings point toward the gut microbiota as a likely explanatory pathway: these medications alter the bacterial communities of the intestines, and those changes may disrupt glucose metabolism.
Because this is an observational study, causation cannot be confirmed. But the scale and consistency of the data carry weight. The authors are not calling for patients to abandon necessary treatment — they are calling for greater care. Doctors are encouraged to weigh long-term prescribing decisions more deliberately, and patients on extended PPI therapy should receive regular blood glucose monitoring to catch any metabolic changes early.
A large study published in the journal Gut suggests that people who take acid reflux medications regularly may face a substantially higher risk of developing type 2 diabetes. The research, released today, recommends that anyone taking these drugs long-term should undergo periodic glucose screening to catch the disease early.
The medications in question are proton pump inhibitors, or PPIs—drugs like omeprazole, pantoprazol, and lansoprazol that suppress stomach acid production. They rank among the ten most widely used medications globally, prescribed not only for reflux but also for peptic ulcers and indigestion. The researchers wanted to understand whether the widespread use of these drugs might be connected to the rising prevalence of type 2 diabetes, which affected 8.5 percent of the global population in 2014.
The study followed 204,689 people—176,050 women and 28,639 men, aged 25 to 75—whose health data had been collected since 1976. Participants updated information about their medical history and health behaviors every two years. Between 2000 and 2004, researchers asked whether participants had used PPIs regularly in the previous two years, defining regular use as two or more times per week. Over a median monitoring period of nine to twelve years, 10,105 participants developed type 2 diabetes.
The numbers tell a striking story. Among regular PPI users, the annual risk of a new diabetes diagnosis was 7.44 cases per 1,000 people. For those who did not take these medications, the rate was 4.32 per 1,000. After accounting for other risk factors—high blood pressure, high cholesterol, physical inactivity, and other medications—regular PPI users were 24 percent more likely to develop type 2 diabetes than non-users. The longer someone took the drugs, the greater the danger. Using PPIs for up to two years raised diabetes risk by 5 percent. Using them for more than two years raised it by 26 percent. Notably, the risk declined the longer someone had been off the medication.
The researchers emphasize that this is an observational study and cannot prove that PPIs directly cause diabetes. However, the scale of the data and the consistency of the findings lend weight to the association. They found that the increased risk did not vary based on gender, age, family history of diabetes, smoking, alcohol consumption, diet, exercise level, cholesterol levels, or regular use of anti-inflammatory drugs—suggesting the effect is robust across different populations.
The team also examined H2 blockers, another class of acid-suppressing medication, and found they carried a 14 percent increased diabetes risk with long-term use. The researchers propose that changes in the gut microbiota—the community of bacteria that normally inhabit the intestines—may help explain why these medications increase diabetes risk. PPIs alter the composition and quantity of these bacteria, and those changes may in turn affect how the body processes glucose.
Given these findings, the study's authors recommend that doctors carefully weigh the benefits and risks before prescribing PPIs for extended periods. For patients who do require long-term treatment, they suggest regular blood glucose screening and monitoring for type 2 diabetes. The message is not that people should stop taking these medications if they need them, but rather that the decision to use them should be made thoughtfully, with awareness of the potential consequences and a plan to monitor for early signs of metabolic trouble.
Notable Quotes
For patients who need long-term treatment, blood glucose screening and type 2 diabetes monitoring are recommended.— Study authors
Doctors should carefully weigh the benefits and risks before prescribing these medications for extended periods.— Researchers
The Hearth Conversation Another angle on the story
Why would a medication that reduces stomach acid affect blood sugar at all? That seems like two separate systems.
That's the intuitive question. The researchers think it comes down to the bacteria in your gut. When you suppress acid production, you change which bacteria thrive and which die off. Those bacterial communities influence how your body absorbs nutrients and regulates glucose. It's not a direct chemical effect—it's ecological.
So this is about the microbiome, not the drug itself?
Partly. The drug changes the microbiome, and the altered microbiome may be what increases diabetes risk. But they haven't proven the mechanism yet. They found the association and have a plausible explanation, but the chain of causation isn't fully established.
The study tracked nearly 205,000 people for a decade. That's huge. Why isn't this more alarming?
Because it's observational, not experimental. They watched what happened; they didn't randomly assign people to take or not take the drugs. People who take PPIs long-term might differ from non-users in ways that also increase diabetes risk—diet, weight, underlying health conditions. The researchers tried to account for those factors, but you can never be certain.
But the risk goes up the longer you take them. That's a dose-response relationship. Doesn't that strengthen the case?
It does. That pattern—more exposure, more risk—is one of the hallmarks of a real causal relationship. It's harder to explain away as coincidence. But it's still not proof.
What should someone do if they've been taking a PPI for years?
The study suggests regular glucose screening. Not panic, not stopping the medication without talking to a doctor. Just awareness and monitoring. For some people, the benefit of controlling reflux outweighs the diabetes risk. For others, there might be alternatives worth exploring. That's a conversation with a physician.